| abstract |
To a TRAIL death receptor comprising a polypeptide having a polypeptide sequence that binds to TRAIL-R1 and TRAIL-R2, which is a multimerization, eg, trimerization domain, and at least one TRAIL death receptor Agonist. Agonists that do not bind to TRAILＴＲ receptors are described. The multimerization domain may be derived from human tetranectin. An agonist can induce apoptosis in pathogenic cells expressing the TRAIL death receptor. Described is a pharmaceutical composition for treating diseases associated with cells expressing DR4 and DR5, eg, tumor cells. Methods for selecting polypeptides and methods for preparing multimeric complexes. |